DTC Stock Overview
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Defence Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$1.72 |
52 Week High | CA$3.85 |
52 Week Low | CA$1.60 |
Beta | 1.5 |
1 Month Change | -9.47% |
3 Month Change | -28.03% |
1 Year Change | -52.22% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.81% |
Recent News & Updates
Shareholder Returns
DTC | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | -1.8% | 0.2% |
1Y | -52.2% | -28.6% | 9.0% |
Return vs Industry: DTC underperformed the Canadian Biotechs industry which returned -27.7% over the past year.
Return vs Market: DTC underperformed the Canadian Market which returned 9.3% over the past year.
Price Volatility
DTC volatility | |
---|---|
DTC Average Weekly Movement | 9.1% |
Biotechs Industry Average Movement | 13.5% |
Market Average Movement | 8.6% |
10% most volatile stocks in CA Market | 18.5% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: DTC's share price has been volatile over the past 3 months.
Volatility Over Time: DTC's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | Sebastien Plouffe | https://defencetherapeutics.com |
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
Defence Therapeutics Inc. Fundamentals Summary
DTC fundamental statistics | |
---|---|
Market cap | CA$76.56m |
Earnings (TTM) | -CA$13.59m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs DTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DTC income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$13.59m |
Earnings | -CA$13.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.30 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -63.9% |
How did DTC perform over the long term?
See historical performance and comparison